BACKGROUND: The risk of acute ischemic stroke (AIS) associated with high estrogen states, including pregnant patients and those using oral contraceptives, has been well documented. We described the histological composition of thrombi collected in these cases. METHODS: From a prospective tissue registry (STRIP registry) of thrombi retrieved during mechanical thrombectomy for AIS, we identified 5 patients with high estrogen states: 1 post-partum patient, 1 undergoing hormone replacement therapy and 3 consuming oral contraceptive pills. Five male control patients were randomly chosen matched by age. Immunohistochemistry for CD42b (platelets), von Willebrand factor (vWF), thrombin-activatable fibrinolysis inhibitor (TAFI), fibrinogen and plasminogen activator inhibitor-1 (PAI-1) was performed. Expression was quantified using Orbit Image Software. Student's t-test was performed as appropriate. RESULTS: Mean TAFI content for the high estrogen state group was higher than controls (25.6 ± 11.9% versus 9.3 ± 9.0%, p = 0.043*). Mean platelet content for the high estrogen state group was lower than controls (41.7 ± 10.6% versus 61.8 ± 12.9%, p = 0.029*). No significant difference was found in vWF, fibrinogen and PAI-1 expression. Mean time to recanalize was higher in the high estrogen state group compared to the control group (57.8 ± 27.6 versus 22.6 ± 11.4 min, p = 0.0351*). The mean number of passes required was higher in the high estrogen group compared to controls 4.6 versus 1.2, p = 0.0261*). CONCLUSIONS: TAFI expression, a powerful driver of thrombosis, was significantly higher in stroke thrombi among patients with high estrogen states compared to controls.

Department of Neurologic Surgery Mayo Clinic Rochester MN USA

Department of Radiology Mayo Clinic 200 1st St SW Rochester MN 55905 USA

Faculty of Medicine in Hradec Kralove Charles University Prague Czech Republic

Henry Ford Hospital Detroit MI USA

See more in PubMed

Rosendaal F r, Helmerhorst F m, Vandenbroucke J p. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol. 2002;22:201–10. doi: 10.1161/hq0202.102318. PubMed DOI

Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012;366:2257–66. doi: 10.1056/NEJMoa1111840. PubMed DOI

DeLoughery TG. Estrogen and thrombosis: controversies and common sense. Rev Endocr Metab Disord. 2011;12:77–84. doi: 10.1007/s11154-011-9178-0. PubMed DOI

Abou-Ismail MY, Citla Sridhar D, Nayak L. Estrogen and thrombosis: a bench to bedside review. Thromb Res. 2020;192:40–51. doi: 10.1016/j.thromres.2020.05.008. PubMed DOI PMC

Kemmeren JM, Algra A, Meijers JCM, Tans G, Bouma BN, Curvers J, Rosing J, Grobbee DE. Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor VLeiden mutation: a randomized trial. Blood. 2004;103:927–33. doi: 10.1182/blood-2003-04-1285. PubMed DOI

Leebeek FWG, Goor MPJ, Guimaraes AHC, Brouwers G-J, Maat MPM, Dippel DWJ, Rijken DC. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost JTH. 2005;3:2211–8. doi: 10.1111/j.1538-7836.2005.01484.x. PubMed DOI

Santamaría A, Oliver A, Borrell M, Mateo J, Belvis R, Martí-Fábregas J, Ortín R, Tirado I, Souto JC, Fontcuberta J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke. 2003;34:2387–91. doi: 10.1161/01.STR.0000088642.07691.15. PubMed DOI

Montaner J, Ribó M, Monasterio J, Molina CA, Alvarez-Sabín J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke. 2003;34:1038–40. doi: 10.1161/01.STR.0000063139.06585.45. PubMed DOI

Fitzgerald S, Wang S, Dai D, Jr, Pandit DHM, Douglas A, Rizvi A, Kadirvel A, Gilvarry R, McCarthy M, Stritt R, Gounis M, Brinjikji MJ, Kallmes W, Doyle DF. Orbit image analysis machine learning software can be used for the histological quantification of acute ischemic stroke blood clots. PLoS ONE. 2019;14:e0225841. doi: 10.1371/journal.pone.0225841. PubMed DOI PMC

Stritt M, Stalder AK, Vezzali E. Orbit image analysis: an open-source whole slide image analysis tool. PLOS Comput Biol. 2020;16:e1007313. doi: 10.1371/journal.pcbi.1007313. PubMed DOI PMC

Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients. J Thromb Haemost JTH. 2007;5:1862–8. doi: 10.1111/j.1538-7836.2007.02665.x. PubMed DOI

Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem. 1998;273:27176–81. doi: 10.1074/jbc.273.42.27176. PubMed DOI

Juhan-Vague I, Renucci JF, Grimaux M, Morange PE, Gouvernet J, Gourmelin Y, Alessi MC. Thrombin-activatable fibrinolysis inhibitor antigen levels and cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2000;20:2156–61. doi: 10.1161/01.ATV.20.9.2156. PubMed DOI

Meijers JC, Middeldorp S, Tekelenburg W, van den Ende AE, Tans G, Prins MH, Rosing J, Büller HR, Bouma BN. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives. Thromb Haemost. 2000;84:9–14. doi: 10.1055/s-0037-1613959. PubMed DOI

Mosnier LO, Buijtenhuijs P, Marx PF, Meijers JCM, Bouma BN. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets. Blood. 2003;101:4844–6. doi: 10.1182/blood-2002-09-2944. PubMed DOI

Suzuki Y, Sano H, Mochizuki L, Honkura N, Urano T. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system. Blood Adv. 2020;4:5501–11. doi: 10.1182/bloodadvances.2020002923. PubMed DOI PMC

Mousa HA, Downey C, Alfirevic Z, Toh C-H. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb Haemost. 2004;92:1025–31. doi: 10.1160/TH04-06-0387. PubMed DOI

Dupuis M, Severin S, Noirrit-Esclassan E, Arnal J-F, Payrastre B, Valéra M-C. Effects of estrogens on platelets and megakaryocytes. Int J Mol Sci. 2019;20:3111. doi: 10.3390/ijms20123111. PubMed DOI PMC